greeksoup/ stock research
Stock research / Foreign companies / PHG · X-Ray Apparatus & Tubes & Related Irradiation Apparatus

Koninklijke Philips N.V. (PHG)

Philips makes medical imaging and treatment equipment, hospital monitoring and informatics systems, sleep and respiratory devices, and personal care products. Koninklijke Philips N.V. is the parent company of the group, and it reports three segments, Diagnosis & Treatment, Connected Care and Personal Health, plus a segment Other holding Innovation & Design, intellectual property royalties, central costs and small items. Figures are stated in euro.

Koninklijke Philips N.V.

Philips makes medical imaging and treatment equipment, hospital monitoring and informatics systems, sleep and respiratory devices, and personal care products. Koninklijke Philips N.V. is the parent company of the group, and it reports three segments, Diagnosis & Treatment, Connected Care and Personal Health, plus a segment Other holding Innovation & Design, intellectual property royalties, central costs and small items. Figures are stated in euro.

Diagnosis & Treatment

This is the largest segment, with sales of €8,531 million in 2025 against €8,790 million the year before, and adjusted EBITA of €998 million against €1,018 million. Comparable sales were flat, after a 3% negative currency and consolidation effect, on mid-single-digit growth in Image Guided Therapy against a low-single-digit decline in Precision Diagnosis. It holds two businesses, Image Guided Therapy and Precision Diagnosis, the latter covering diagnostic imaging products, solutions and services including an ultrasound business unit. The filing gives its positions as number one in image guided therapy, number one in cardiovascular ultrasound and number three in diagnostic imaging. The stated strategy is to integrate imaging systems with informatics, combining diagnostic and therapeutic devices with clinical software and services.

Connected Care

Sales were €5,076 million against €5,134 million, with adjusted EBITA of €544 million against €494 million. Comparable sales rose 3%, which the filing attributes to mid-single-digit growth in Monitoring and low single-digit growth in Enterprise Informatics. It holds three businesses: Monitoring, Enterprise Informatics and Sleep & Respiratory Care. The filing gives its positions as number one in hospital and ambulatory monitoring, number one in picture archiving and communication systems and interoperability, and number two in sleep therapy devices and masks.

Personal Health

Sales were €3,673 million against €3,486 million, the only segment to grow, with adjusted EBITA of €662 million against €584 million, and comparable sales grew 8%. It runs three business units, Personal Care, Oral Healthcare and Mother and Child Care, and the filing gives its positions as number one in grooming, number two in oral healthcare and number two in infant feeding.

The group and Other

The Other segment had sales of €554 million against €611 million and an adjusted EBITA loss of €9 million, the fall in sales coming mainly from lower royalty income. Group sales were €17,834 million against €18,021 million, 1% lower on a nominal basis but 2% higher on a comparable basis after a 3% negative currency effect, and comparable order intake increased 6%. Group adjusted EBITA was €2,195 million against €2,077 million, or 12.3% of sales against 11.5%. Depreciation and amortisation was €1,125 million against €1,390 million.

People

Headcount was 66,401 at the end of 2025, against 67,823 a year earlier and 69,656 in 2023. Approximately 55% of the workforce sits in what the company calls mature geographies and 45% in growth geographies, against 56% and 44% a year earlier. Headcount in mature geographies fell by 1,471 during 2025 while growth geographies added 133, and Western Europe held 15,807 people at the year end.

Quality and the regulator

The company continued to work under the consent decree requirements for Respironics in the US during 2025. The US Food and Drug Administration inspected nine global facilities in early 2025, and observations at three sites resulted in a warning letter in September 2025, which the company says it is committed to resolving.

From Philips' annual report on Form 20-F for the year ended 31 December 2025. That filing carries no Item 4 or Item 5 heading in its body, using a cross-reference index at the back instead, so the annual report is read as one whole document rather than from separately located sections. The filing

Compare with another name

Koninklijke Philips N.V. files a 20-F with the SEC once a year, in euros. In the year to 31 December 2025 it reported revenue of EUR 17,834 million ($20.2 billion at the year's average rate), down 1.0% on the year before. Its profit attributable to shareholders was EUR 895 million, and diluted earnings per share EUR 0.93.

Koninklijke Philips (PHG) in brief

Koninklijke Philips (PHG) reported revenue of EUR 17.8 billion for the year to 31 December 2025, down 1.0% on the year before.
Read moreProfit attributable to shareholders was EUR 895 million and diluted earnings per share EUR 0.93. Revenue was EUR 18.0 billion in 2024, EUR 18.2 billion in 2023, EUR 17.8 billion in 2022 and EUR 17.2 billion in 2021. Profit attributable to shareholders in the same years was a loss of EUR 702 million, a loss of EUR 466 million, a loss of EUR 1.6 billion and EUR 3.3 billion. Revenue grew 0.6% a year, compounded, over the five years to 2025. At the close of 10 November 2026 the market cap of Koninklijke Philips was $29.3 billion, 29.3 times its earnings for 2025.

The share in the US

Last close$30.40 on 10 November 2026
52-week range$23.81 (1 October 2026) to $32.91 (10 February 2026)
Over one yearup 7.6%
Market cap$29.3 billion: 962,920,132 shares outstanding at 31 December 2025 (20-F), each US share standing for one ordinary share
P/E, latest fiscal year29.3: the last close over diluted EPS for the year to Dec 2025, EUR 0.93 per ordinary share, $1.04 at 1.1154 US dollars per EUR on 6 November 2026 (FRED DEXUSEU). The company reports once a year, so this is the latest fiscal year, not the last four quarters.

US dollars per share as it trades in the US; the market cap and the P/E are worked out here, not filed. Prices from IEX, for splits.

Ratios

From the latest annual report, the year to Dec 2025, in dollars

ROE8.2%
ROCE7.5%
Operating margin8.0%
Net margin5.0%
FCF margin5.0%
Interest cover4.12
Debt to equity0.74
Cash conversion1.30
Share count, last 12 months1.6%
Sales CAGR, 3 years0.0%
Profit CAGR, 3 yearsn/a
EPS$1.04

At the close of 10 November 2026

Price$30.40
Market cap$29.3 billion
Stock P/E29.31
Price to book2.40
EV / EBITDAn/a
Dividend yield1.3%
Market cap / sales1.47
52-week high$32.91
52-week low$23.81
Price, 1 year7.6%
Price CAGR, 3 yearsn/a
Price CAGR, 5 yearsn/a
Worked from the filed figures; hover a name for the formula.
Read moreThe priced ones use the latest price, the last regular-hours trade on IEX. Debt to equity here stands on the borrowings total Koninklijke Philips N.V. states in its annual report, never added up from its parts; lease liabilities are a separate line. Nothing here is a valuation or a view.
PHGgreeksoup.ai
Daily prices to 10 November 2026, adjusted for splits; from 28 September 2026 each day's price is the last regular-hours trade on IEX.
Read moreData provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. Day by day for the last three years; before that one point a week, carrying the week's last close and its average daily volume, so a volume bar means the same thing across the whole series; the bars sit under the price on their own scale, on the right. The moving averages need consecutive days and are drawn from the daily part. This company reports once a year, so every view here moves once a year, on the day each annual report was filed, and holds until the next. P/E is the close over the year's EPS per US share: the EPS as filed, in dollars at the year's average exchange rate (Federal Reserve, from FRED). Sales and margin are each year's revenue in dollars and its operating margin. EV/EBITDA, price to book and market cap to sales set the close against that year's balance sheet in dollars at its year-end rate and its share count per US share. The dashed line is the median over the range shown. The P/E above uses today's exchange rate, so the latest point here can differ from it a little. Drawn in your browser; the range and overlay you pick are remembered here only.

The public record on PHG

DividendsEUR 0.85 a share in FY2025
Filings12 in twelve months: 10 reports on Form 6-K, most often philips announces exchange ratio for 2025 dividend (1); philips shareholders approve all proposals at the AGM 2026 (1); philips convenes the Annual General Meeting of Shareholders 2026 (1); philips proposes new appointment and re-appointments to its Supervisory Board and CEO re-appointment (1); annual Report 2025 Better care for more people (1)
Planned insider salesno Form 144 notice in twelve months
Options tapeput/call 1.24 by open interest at the 10 November 2026 close; the straddle prices a 3.7% move to 20 November 2026
13F holders366 funds reported a position for the quarter to 30 June 2026; largest Mondrian Investment Partners LTD
Congress0 House trades disclosed in six months
Short interest2.1 million shares short, 1.71 days to cover at 30 October 2026

Income statement (profit and loss), 11 fiscal years

Year toDec 2015Dec 2016Dec 2017Dec 2018 †Dec 2019 †Dec 2020 †Dec 2021Dec 2022 †Dec 2023Dec 2024Dec 2025
Revenue16,80617,42217,78018,12117,14717,31317,15617,82718,16918,02117,834
Cost of sales9,5949,4849,6009,5689,2499,4939,98810,63310,72110,2489,776
Gross profit7,2127,9398,1818,5547,8997,8207,1687,1947,4487,7738,058
Research and development1,5621,6691,7641,7591,7901,8221,8062,0911,8901,7471,700
Operating profit6581,4641,5171,7191,3661,264553-1,529-1155291,424
Finance costs453507263264233202188258376387346
Profit before tax3291,0341,3771,5031,2481,211509-1,731-5261231,182
Income tax169203349193258212-103-113-73.0963282
Profit for the year6381,4911,8701,0971,1731,1953,323-1,605-463-698897
Profit attributable to shareholders6241,4481,6571,0901,1671,1873,319-1,608-466-702895
Filing20-F20-F20-F20-F20-F20-F20-F20-F20-F20-F20-F
EUR million, from each year's annual report on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed.
Read moreA line the company does not file under the standard tag is left out rather than estimated. A year marked † shows the figure as the company restated it in a later annual report (Dec 2018, Dec 2019, Dec 2020, Dec 2022); the first-filed figure is in the CSV. Profit for the year includes the part that belongs to minority shareholders; profit attributable to shareholders is the part EPS is struck on. Each year links to its own page.
Year toDec 2015Dec 2016Dec 2017Dec 2018 †Dec 2019 †Dec 2020 †Dec 2021Dec 2022 †Dec 2023Dec 2024Dec 2025
Diluted EPS0.681.561.751.141.251.293.50-1.69-0.49-0.750.93
Basic EPS0.681.581.781.161.271.313.52-1.69-0.49-0.750.94
Filing20-F20-F20-F20-F20-F20-F20-F20-F20-F20-F20-F

EUR per ordinary share, as filed. One US-listed share can stand for more or fewer ordinary shares; the P/E above puts the two on the same basis.

Revenue by segment

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025Share
of the parts, latest year
Diagnosis & Treatment6,4846,6867,3657,7268,4858,1757,8258,3038,8258,7908,53147.8%
Connected Caren/an/a4,3314,3414,6745,5435,3715,2685,1385,1345,07628.5%
Personal Health6,7517,0995,6855,5243,5163,1993,4293,6263,6023,4863,67320.6%
Othern/a4794005304723965306306046115543.1%
Connected Care & Health Informatics3,0223,158n/an/an/an/an/an/an/an/an/an/a
HealthTech Other503n/an/an/an/an/an/an/an/an/an/an/a
Legacy Items46.0n/an/an/an/an/an/an/an/an/an/an/a
Diagnosis & TreatmentConnected Care FY2017 to FY2025Personal HealthOther FY2016 to FY2025Connected Care & Health Informatics FY2015 to FY2016HealthTech Other FY2015Legacy Items FY2015
16.8Dec 201517.8Dec 201717.1Dec 201917.2Dec 202118.2Dec 202317.8Dec 2025

EUR billion; hover a block for its figure and share; a part named with years is one the company split its revenue into only then

EUR million, from the latest 20-F, in the company's own words. A year is shown only where the parts add up to the revenue above.

Revenue by region

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025Share
of the parts, latest year
United States5,7425,9486,0846,0506,6266,5806,4037,2267,1787,2277,13040.0%
Other countries5,7495,8915,9356,0874,8985,0244,1505,6885,6795,5965,42130.4%
Netherlands3743934145103914041,8602,0212,3902,5062,54614.3%
Chinan/an/an/a2,3802,4272,3191,4001,2391,4081,1531,2026.7%
Japan9621,1031,0591,0451,1851,1131,0681,0119418868835.0%
Germany9299651,0111,0328059809706425736536523.7%
France487513530519380383446n/an/an/an/an/a
India431399425498n/an/a431n/an/an/an/an/a
Switzerland2,1322,2102,322n/an/an/an/an/an/an/an/an/a
United Kingdomn/an/an/an/a436509426n/an/an/an/an/a
United StatesOther countriesNetherlandsChina FY2018 to FY2025JapanGermanyFrance FY2015 to FY2021Switzerland FY2015 to FY2017Other
16.8Dec 201517.8Dec 201717.1Dec 201917.2Dec 202118.2Dec 202317.8Dec 2025

EUR billion; hover a block for its figure and share; a part named with years is one the company split its revenue into only then

EUR million, from the latest 20-F, in the company's own words. A year is shown only where the parts add up to the revenue above.

Cash flow statement

Year toDec 2015Dec 2016Dec 2017Dec 2018 †Dec 2019 †Dec 2020 †Dec 2021Dec 2022 †Dec 2023Dec 2024Dec 2025
Cash from operations1,3592,2072,2201,765n/a2,6401,714-2002,2591,5561,162
Purchase of property, plant and equipmentn/an/a420422486485397444345317269
Free cash flown/an/a1,8001,343n/a2,1551,317-6441,9141,239893
Depreciation and amortisation9729761,0251,0891,3431,4621,3231,6021,2611,3901,125
Buybacksn/an/a6421,0421,3763431,6361876624110.0
Dividends paidn/an/a3844014531.04824122.01.0328
Filing20-F20-F20-F20-F20-F20-F20-F20-F20-F20-F20-F
EUR million, from the cash flow statement as filed.
Read morePurchase of property, plant and equipment is the cash line as filed; purchases of intangible assets and acquisitions are not in it. Free cash flow is cash from operations less that purchase, arithmetic on the two filed lines. Cash from investing and from financing are the company's own section totals, below zero where cash went out. Buybacks are the cash paid for the company's own shares.

Balance sheet at year end

Year toDec 2015Dec 2016Dec 2017Dec 2018 †Dec 2019 †Dec 2020 †Dec 2021Dec 2022 †Dec 2023Dec 2024Dec 2025
Funded by
Equity attributable to shareholders11,60712,54611,99912,08812,59711,87014,43813,24912,02812,00610,957
Non-controlling interests11890724.029.028.031.036.034.033.037.032.0
Borrowings, as filed5,7605,6064,7154,8215,4476,9346,9808,2017,6897,6398,084
Lease liabilitiesn/an/an/a1,133256n/an/an/a1,0741,073963
Other liabilitiesn/a13,2118,5777,9488,6888,8789,5079,2048,5828,2216,908
Total equity and liabilitiesn/a32,27025,31526,01927,01627,71330,96130,68829,40628,97626,944
Owned
Property, plant and equipment2,3222,1551,5911,7122,8662,6822,6992,6382,4832,4522,217
Goodwilln/a8,8987,7318,5038,6548,01410,63710,2389,87610,3839,271
Other intangible assets3,6933,5523,3223,5893,4662,9973,6503,5263,1902,9822,569
Cash and cash equivalents1,7662,3341,9391,6881,4253,2262,3031,1721,8692,4012,794
Trade and other receivablesn/a5,3273,9094,0354,5544,1563,7874,1153,7333,6723,530
Inventoriesn/a3,3922,3532,6742,7732,9933,4504,0493,4913,1982,870
Other assetsn/a6,6124,4703,8183,2783,6454,4354,9504,7643,8883,693
Total assetsn/a32,27025,31526,01927,01627,71330,96130,68829,40628,97626,944
Filing20-F20-F20-F20-F20-F20-F20-F20-F20-F20-F20-F
EUR million, at each fiscal year end.
Read moreBoth totals are the company's own; other liabilities and other assets are each total less the rows shown. Borrowings is the company's own stated total where it files one; it is never added up from its parts here.

Ratios on the filed lines

Year toDec 2015Dec 2016Dec 2017Dec 2018 †Dec 2019 †Dec 2020 †Dec 2021Dec 2022 †Dec 2023Dec 2024Dec 2025
Gross margin42.9%45.6%46.0%47.2%46.1%45.2%41.8%40.4%41.0%43.1%45.2%
Operating margin3.9%8.4%8.5%9.5%8.0%7.3%3.2%-8.6%-0.6%2.9%8.0%
Net margin3.7%8.3%9.3%6.0%6.8%6.9%19.3%-9.0%-2.6%-3.9%5.0%
Free cash flow marginn/an/a10.1%7.4%n/a12.4%7.7%-3.6%10.5%6.9%5.0%
Return on year-end equity5.4%11.5%13.8%9.0%9.3%10.0%23.0%-12.1%-3.9%-5.8%8.2%
Effective tax rate51.4%19.6%25.3%12.8%20.7%17.5%-20.2%n/an/a782.9%23.9%
Filing20-F20-F20-F20-F20-F20-F20-F20-F20-F20-F20-F

Arithmetic on the filed lines of the same year: margins over revenue, return on equity as profit attributable to shareholders over year-end equity, tax over profit before tax.

Questions

What was Koninklijke Philips' revenue in 2025?

Koninklijke Philips (PHG) reported revenue of EUR 17.8 billion for the year to 31 December 2025, down 1.0% on the year before.

How much did Koninklijke Philips earn in 2025?

Profit attributable to shareholders was EUR 895 million for the year to 31 December 2025, and diluted earnings per share EUR 0.93.

What is Koninklijke Philips' P/E ratio?

At the close of 10 November 2026, Koninklijke Philips traded at 29.3 times its earnings for 2025.

What is Koninklijke Philips' market cap?

The market cap of Koninklijke Philips was $29.3 billion at the close of 10 November 2026.

Peers: Medical Equipment

CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Edwards Lifesciences Corp. EW$59.9 billion58.779.4%21.6%13.4%0.06n/a
Becton Dickinson & Co. BDX$57.9 billion64.043.9%9.6%-2.6%0.692.0%
Medline Inc. MDLN$53.8 billion59.444.9%5.7%n/a1.07n/a
GE HealthCare Technologies Inc. GEHC$37.8 billion17.6518.5%13.3%6.9%0.860.2%
Resmed Inc. RMD$32.9 billion21.3226.8%33.0%9.0%0.071.1%
Dexcom Inc. DXCM$29.8 billion31.3339.1%24.0%13.0%0.49n/a
Koninklijke Philips N.V. PHG *$29.3 billion29.318.2%8.0%-1.0%0.741.3%
West Pharmaceutical Services Inc. WST$28.8 billion46.3221.5%23.0%12.6%0.070.2%
Steris plc STE$25.0 billion30.5011.4%19.0%8.1%0.261.0%
Zimmer Biomet Holdings, Inc. ZBH$20.3 billion27.166.0%13.6%7.0%0.590.9%
Solventum Corp. SOLV$15.3 billion101.213.2%5.6%-2.8%1.05n/a
Butterfly Network, Inc. BFLY$1.7 billionn/a-29.1%-46.9%39.3%0.000.0%
All 110 in Medical Equipment
CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Intuitive Surgical Inc. ISRG$156.0 billion54.4118.5%28.4%20.5%0.00n/a
Medtronic plc MDT$130.1 billion25.0310.4%18.1%9.8%0.562.8%
Stryker Corp. SYK$123.4 billion34.5215.4%20.7%7.9%0.641.1%
3M Co. MMM$97.9 billion28.2285.7%18.8%1.7%3.631.6%
Boston Scientific Corp. BSX$64.8 billion18.9413.7%18.7%8.9%0.47n/a
Edwards Lifesciences Corp. EW$59.9 billion58.779.4%21.6%13.4%0.06n/a
Becton Dickinson & Co. BDX$57.9 billion64.043.9%9.6%-2.6%0.692.0%
Medline Inc. MDLN$53.8 billion59.444.9%5.7%n/a1.07n/a
GE HealthCare Technologies Inc. GEHC$37.8 billion17.6518.5%13.3%6.9%0.860.2%
Resmed Inc. RMD$32.9 billion21.3226.8%33.0%9.0%0.071.1%
Dexcom Inc. DXCM$29.8 billion31.3339.1%24.0%13.0%0.49n/a
Koninklijke Philips N.V. PHG *$29.3 billion29.318.2%8.0%-1.0%0.741.3%
West Pharmaceutical Services Inc. WST$28.8 billion46.3221.5%23.0%12.6%0.070.2%
Steris plc STE$25.0 billion30.5011.4%19.0%8.1%0.261.0%
Zimmer Biomet Holdings, Inc. ZBH$20.3 billion27.166.0%13.6%7.0%0.590.9%
Solventum Corp. SOLV$15.3 billion101.213.2%5.6%-2.8%1.05n/a
Glaukos Corp. GKOS$14.0 billionn/a-23.7%-25.5%46.9%0.00n/a
Baxter International Inc. BAX$13.7 billionn/a-11.1%-1.9%5.3%1.322.0%
Smith & Nephew plc SNN *$13.6 billion21.5911.8%12.9%6.1%0.592.4%
Penumbra Inc. PEN$12.7 billion80.959.9%12.1%17.0%0.00n/a
Align Technology Inc. ALGN$12.3 billion25.3911.4%14.9%4.4%0.00n/a
Cooper Companies, Inc. COO$12.1 billion21.696.8%12.8%4.7%0.31n/a
Insulet Corp. PODD$10.3 billion24.1127.2%18.4%26.5%0.61n/a
Globus Medical Inc. GMED$10.1 billion18.4911.6%21.6%13.4%0.00n/a
Bausch & Lomb Corp. BLCO$7.6 billionn/a-1.7%7.1%8.9%0.79n/a
MSA Safety Inc. MSA$6.7 billion22.5021.1%20.2%8.1%0.781.2%
Teleflex Inc. TFX$6.2 billion18.878.7%9.4%20.9%0.460.9%
Haemonetics Corp. HAE$5.6 billion54.8911.6%12.8%4.1%1.26n/a
Merit Medical Systems Inc. MMSI$5.3 billion33.039.2%13.5%9.1%0.42n/a
LivaNova plc LIVN$5.0 billion30.3814.3%10.7%11.7%0.22n/a
MiniMed Group, Inc. MMED$4.9 billionn/an/an/an/a0.00n/a
Heartflow, Inc. HTFL$4.8 billionn/a-42.3%-37.8%n/a0.00n/a
ICU Medical Inc. ICUI$4.6 billion76.242.8%5.1%-5.9%0.53n/a
Integer Holdings Corp. ITGR$4.3 billion42.496.0%8.2%-0.3%0.71n/a
Envista Holdings Corp. NVST$4.1 billion6.6820.5%25.4%9.8%0.46n/a
Pulse Biosciences, Inc. PLSE$4.0 billionn/a-45.6%-5,821.1%1,637.2%0.00n/a
Warby Parker Inc. WRBY$3.8 billion498.421.9%0.2%9.9%0.00n/a
TransMedics Group, Inc. TMDX$3.2 billion24.6426.2%11.9%28.5%0.930.0%
Axogen, Inc. AXGN$3.0 billionn/a-6.4%-5.2%24.3%0.00n/a
AtriCure, Inc. ATRC$2.9 billion187.452.8%2.9%13.8%0.11n/a
iRhythm Holdings, Inc. IRTC$2.9 billionn/a-21.8%-5.7%21.6%3.68n/a
UFP Technologies Inc. UFPT$2.4 billion31.9615.8%15.5%8.6%0.20n/a
Establishment Labs Holdings Inc. ESTA$2.0 billionn/a-246.6%-6.6%38.3%17.17n/a
Dentsply Sirona Inc. XRAY$1.9 billionn/a-8.9%-1.5%-1.4%1.626.6%
Lemaitre Vascular Inc. LMAT$1.8 billion28.7114.7%27.7%11.8%0.391.2%
Inspire Medical Systems, Inc. INSP$1.8 billion18.1212.2%1.8%-0.2%0.00n/a
Kestra Medical Technologies, Ltd. KMTS$1.8 billionn/a-67.4%-134.5%60.7%0.33n/a
Butterfly Network, Inc. BFLY$1.7 billionn/a-29.1%-46.9%39.3%0.000.0%
Enovis Corp. ENOV$1.6 billionn/a-35.3%-20.6%3.3%0.84n/a
Conmed Corp. CNMD$1.5 billion21.146.9%9.9%1.6%0.771.2%
National Vision Holdings, Inc. EYE$1.5 billion31.165.6%4.1%7.8%0.26n/a
Cadre Holdings, Inc. CDRE$1.5 billion35.5811.2%10.7%18.3%1.011.2%
NovoCure Ltd. NVCR$1.4 billionn/a-34.7%-17.2%12.9%0.56n/a
Procept BioRobotics Corp. PRCT$1.3 billionn/a-34.9%-33.6%17.5%0.16n/a
Tandem Diabetes Care Inc. TNDM$1.3 billionn/a-36.4%-2.4%6.8%4.47n/a
Staar Surgical Co. STAA$1.2 billion1,717,853,041,864,201,984.000.1%0.2%42.4%0.00n/a
Integra LifeSciences Holdings Corp. IART$1.1 billion85.441.2%4.4%0.8%1.71n/a
Si-Bone, Inc. SIBN$1.1 billionn/a-7.4%-7.6%14.0%0.190.0%
Iradimed Corp. IRMD$1.1 billion46.4322.5%32.3%11.0%0.000.9%
Alphatec Holdings, Inc. ATEC$1.1 billionn/an/a-3.6%15.3%n/an/a
Ceribell, Inc. CBLL$1.1 billionn/a-62.9%-69.8%31.3%0.17n/a
Artivion, Inc. AORT$999 millionn/a-3.9%2.3%14.0%0.81n/a
Bioventus Inc. BVS$942 million13.9723.8%9.7%3.9%0.96n/a
Beta Bionics, Inc. BBNX$898 millionn/a-20.7%-72.7%43.7%0.00n/a
Orthopediatrics Corp. KIDS$873 millionn/a-10.0%-9.4%16.1%0.31n/a
Delcath Systems, Inc. DCTH$699 million125.565.0%5.2%38.1%0.00n/a
Tactile Systems Technology Inc. TCMD$599 million25.8410.5%9.4%14.4%0.00n/a
Sight Sciences, Inc. SGHT$594 millionn/a-57.8%-29.5%16.2%0.83n/a
Anteris Technologies Global Corp. AVR$572 millionn/a-47.7%-4,880.4%9.0%0.00n/a
Avita Medical, Inc. RCEL$545 millionn/an/a-33.9%17.0%n/an/a
Angiodynamics Inc. ANGO$512 millionn/a-20.1%-11.2%8.2%0.00n/a
Mimedx Group, Inc. MDXG$490 millionn/a-9.1%-8.3%-22.8%0.00n/a
Shoulder Innovations, Inc. SI$458 millionn/a-28.2%-54.4%n/a0.13n/a
NeuroPace Inc. NPCE$435 millionn/a-160.9%-15.3%11.6%4.970.0%
Mobia Medical, Inc. MOBI$406 millionn/an/an/an/a0.05n/a
Carlsmed, Inc. CARL$404 millionn/a-52.9%-59.0%n/a0.20n/a
Cerus Corp. CERS$394 millionn/a-9.7%-1.0%n/a0.84n/a
Cytosorbents Corp. CTSO$364 millionn/an/a-34.7%3.1%n/an/a
Embecta Corp. EMBC$363 million4.33n/a21.9%-7.6%n/a7.2%
Orchestra BioMed Holdings, Inc. OBIO$352 millionn/a-731.8%-195.4%1,007.4%4.58n/a
SS Innovations International, Inc. SSII$322 millionn/a-23.3%-15.8%89.7%0.00n/a
CapsoVision, Inc. CV$320 millionn/a-226.6%-217.1%n/a0.00n/a
Treace Medical Concepts, Inc. TMCI$320 millionn/a-90.5%-24.4%-7.1%0.91n/a
InfuSystem Holdings, Inc. INFU$306 million33.9314.7%9.8%2.4%0.31n/a
Sanara MedTech Inc. SMTI$291 millionn/a-403.0%n/a12.9%5.85n/a
Orthofix Medical Inc. OFIX$290 millionn/a-10.5%-2.5%2.1%0.52n/a
ClearPoint Neuro, Inc. CLPT$281 millionn/a-132.5%-70.6%32.5%1.86n/a
Profound Medical Corp. PROF$281 millionn/a-76.4%-145.1%65.3%0.11n/a
Utah Medical Products Inc. UTMD$232 million22.228.6%28.4%-7.0%0.00n/a
Orasure Technologies Inc. OSUR$229 millionn/a-15.8%-43.8%-7.5%0.00n/a
PRO DEX Inc. PDEX$226 million19.4024.4%16.8%13.3%0.33n/a
Electromed, Inc. ELMD$225 million19.8022.7%19.5%14.1%0.00n/a
RxSight, Inc. RXST$205 millionn/a-20.9%-50.4%-14.3%0.00n/a
Anika Therapeutics, Inc. ANIK$180 millionn/a-1.3%-2.1%9.4%0.00n/a
TriSalus Life Sciences, Inc. TLSI$175 millionn/a-3,861.0%-63.0%15.4%47.60n/a
Edap TMS SA FOCL$167 millionn/a-104.3%-35.4%n/a0.99n/a
Inogen Inc. INGN$157 millionn/a-22.6%-11.6%-2.3%0.00n/a
Koru Medical Systems, Inc. KRMD$147 millionn/a-4.2%-1.3%18.4%0.02n/a
Apyx Medical Corp. APYX$125 millionn/a-87.6%-5.5%24.4%3.89n/a
Pulmonx Corp. LUNG$122 millionn/a-124.4%-44.4%-3.2%1.11n/a
SkinHealth Systems Inc. SKIN$103 millionn/a-32.8%2.4%-4.4%4.36n/a
Stereotaxis, Inc. STXS$103 millionn/a-182.3%-75.7%-5.5%0.00n/a
Lakeland Industries Inc. LAKE$92 millionn/a-21.4%-4.1%-0.4%0.23n/a
Neuraxis, Inc. NRXS$87 millionn/a-334.1%-186.2%94.3%0.06n/a
Outset Medical, Inc. OM$80 millionn/a-85.4%-51.2%1.6%1.18n/a
Lucid Diagnostics Inc. LUCD$77 millionn/a-478.3%-930.8%24.9%2.15n/a
NutriBand Inc. NTRB$71 millionn/a-130.7%-435.6%-37.3%0.00n/a
RenovoRx, Inc. RNXT$57 millionn/a-140.2%-489.0%n/a0.00n/a
Lensar, Inc. LNSR$57 millionn/a304.4%-3.3%1.6%0.17n/a
PAVmed Inc. PAVM$10 millionn/a-34.5%-23,841.1%-89.0%0.43n/a
2 companies share its SEC industry code (X-Ray Apparatus & Tubes & Related Irradiation Apparatus); the rest are the names nearest in size in its wider industry, Medical Equipment, one of the Fama-French 48 industries, a published grouping of SEC industry codes.
Read moreBy market capitalisation; a click on a heading sorts by it, largest first, and a second click turns it round. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close; a name marked * is a foreign company that files once a year, on its latest fiscal year.

Annual reports on EDGAR

FormYear toFiled
20-F31 December 202519 February 2026EDGAR
20-F31 December 202421 February 2025EDGAR
20-F31 December 202320 February 2024EDGAR
20-F/A31 December 202224 February 2023EDGAR
20-F31 December 202221 February 2023EDGAR
20-F31 December 202122 February 2022EDGAR
20-F31 December 202023 February 2021EDGAR
20-F31 December 201925 February 2020EDGAR
20-F31 December 201827 February 2019EDGAR
20-F31 December 201720 February 2018EDGAR
20-F31 December 201621 February 2017EDGAR
20-F31 December 201523 February 2016EDGAR